戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nts fully protected mice from challenge with virulent virus.
2 tion in domestic pigs against challenge with virulent virus.
3  this pandemic, consistent with an unusually virulent virus.
4 ytogenes into rJ.M(Y135Q) generated a highly virulent virus.
5  gene 71 did not result in the generation of virulent virus.
6 otection against challenge with the parental virulent virus.
7 ction after experimental challenge with this virulent virus.
8 noculated with similar doses of the parental virulent virus.
9 (H353K) mice, we generated and cloned a more virulent virus.
10 daptation, are not sufficient to result in a virulent virus.
11 rts to develop vaccines against these highly virulent viruses.
12 ith two copies of nsP3 from SFV6 resulted in virulent viruses.
13  brain and spinal cord as efficiently as the virulent viruses.
14 e of resistance to superinfection with fully virulent viruses.
15  comprehensive immunity without spawning new virulent viruses.
16            The low rates of change for these virulent viruses (7.05 x 10(-5) and 2.05 x 10(-5) per ye
17 ry early during infection was converted to a virulent virus after NF-kappaB inhibition.
18 etely protected against challenge with live, virulent virus after receiving two 0.15-microg doses of
19        Following challenge with the parental virulent virus, all pigs immunized by the intramuscular
20  constructed from cDNA clones derived from a virulent virus and from two attenuated viruses adapted t
21 al (anterograde and retrograde) transport of virulent virus and unidirectional (retrograde) transport
22 that are heavily depleted, if not devoid, of virulent viruses and that such viruses, if reintroduced,
23 rus-neutralizing antibodies to this uniquely virulent virus, and that humans can sustain circulating
24 a tissue predilection similar to that of the virulent virus, and vice versa.
25 ining virulent virus may be safe, as long as virulent viruses are present at levels below a critical
26 duction in the Republic of Georgia, a highly virulent virus, ASFV Georgia 2007 (ASFV-G), has caused a
27 -dose subcutaneous vaccination followed by a virulent virus challenge 6 months later.
28 rate) were immune to disease upon homologous virulent virus challenge at postinoculation day (PID) 21
29  provided 100% protection from disease after virulent virus challenge.
30 ited protection from detectable infection by virulent virus challenge.
31 d to be highly protective against homologous virulent virus challenges in type I interferon receptor
32          Southern blot analysis of recovered virulent viruses confirmed that they were recombinant E7
33 encephalitis virus (EEEV) is one of the most virulent viruses endemic to North America.
34 c virus with the HN protein derived from the virulent virus exhibited a tissue predilection similar t
35 -to-bacteria ratios such as feces, creating "virulent virus-free" controls.
36 rate that colony isolation reliably excludes virulent viruses from sample sources with low virion-to-
37 e found two phylogenetically related, highly virulent viruses (genus Ranavirus, family Iridoviridae)
38                             Attenuation of a virulent virus is a proven approach for generating vacci
39 c CVB3 strain, created from sequences of two virulent viruses, is sufficiently attenuated to act as a
40  a vaccine against virulent ASFV-G, a highly virulent virus isolate detected in the Caucasus region i
41 ssible that the source of some of the recent virulent viruses isolated from poultry and wild birds mi
42                Both parental and recombinant virulent viruses led to high levels of viremia and titer
43 ate that live-attenuated vaccines containing virulent virus may be safe, as long as virulent viruses
44 nfluenza in Hong Kong was caused by a highly virulent virus of avian origin.
45 etic analysis and pathotyping confirmed that virulent viruses of different genotypes are circulating
46 lated to this group since 1986 suggests that virulent viruses of this genotype may have evolved unnot
47 f5(-/-)Irf7(-/-) mice were protected against virulent virus re-challenge.
48                                   The highly virulent viruses replicated to high titers in the mouse
49 ucosal immunity to reinfection with a highly virulent virus requires the accumulation and persistence
50  neglected until the recent emergence of two virulent viruses, severe fever with thrombocytopenia syn
51  immunity and the possible emergence of more virulent virus strains may also contribute.
52 wborns inoculated with either tumorigenic or virulent virus strains, and (iii) dominant or semidomina
53 ock the spread of potentially tumorigenic or virulent virus strains.
54 me in a bioreactor model of the human colon, virulent viruses target susceptible strains without sign
55   These results suggest that TR339, the most virulent virus tested, attaches to cells through a low-a
56 P3 of SFV6 with that of A774wt resulted in a virulent virus; the virulence of this recombinant was st
57  (LAVs), generated by multiple passages of a virulent virus through embryonated hens' eggs.
58 nuated viruses may limit the pathogenesis of virulent viruses, thus establishing a virulence threshol
59 required for pathogenicity or whether a more virulent virus variant had evolved, we generated a molec
60  CNS cells survive acute infection with this virulent virus, we developed a recombinant JHMV that exp
61 CRB adults in Palau are infected with a less virulent virus, which may affect the nature and extent o
62  a series of challenges ending with a highly virulent virus with a primary isolate envelope heterolog